

价值引领，开放赋能——国际资本投资并购新机遇
Value-Driven, Openness-Empowered, New Investment and M&A Opportunities for Global Investors

上海证券交易所国际投资者大会 Shanghai Stock Exchange Global Investors Conference

2025年11月13日

November 13, 2025

行业论坛 / Industry Panels

圆桌讨论 / Panel

AI时代的中国产业新格局 The New Landscape of China's Industry in the AI Era

讨论嘉宾 / Panelists




戴伟民 Wayne DAI

芯原股份董事长兼总裁
Chairman, President and CEO, VeriSilicon

戴伟民，芯原股份创始人、董事长兼总裁，曾任美国Celestry共同董事长兼首席技术长，美国Ultima创始人、董事长兼总裁。他是加州大学伯克利分校计算机科学学士和电子工程博士，曾任加州大学圣克鲁兹分校计算机工程系终身教授。目前，他担任中国半导体行业协会集成电路设计分会副理事长，上海开放处理器产业创新中心理事长，上海市集成电路行业协会副会长等多个重要职务。

Dr. Wayne Dai is the founder, chairman of the board of directors, President and Chief Executive Officer of VeriSilicon. Prior to founding VeriSilicon, Dr. Dai was the Co-Chairman and Chief Technology Officer of Celestry Technologies, Inc., as well as the founder, chairman of the board of directors, and Chief Executive Officer of Ultima Interconnect Technology, Inc. Dr. Dai received his Bachelor's degree in Computer Science and his Ph.D. degree in Electrical Engineering from the University of California at Berkeley. He was a professor in the department of Computer Engineering at the University of California at Santa Cruz. Dr. Dai currently serves as the Vice President of the China Semiconductor Industry Association IC Design Branch, the President of the Shanghai Open Processor Innovation Center, the Vice President of Shanghai Integrated Circuit Industry Association and other multiple key positions.



徐柳 XU Liu

金山办公副总裁
Vice President, Kingsoft Office

徐柳，金山办公副总裁，负责公司资本市场相关工作及国际业务拓展。在加入金山办公前，徐柳女士就职于中金公司投资银行部，并担任董事总经理，曾主导TMT、消费等领域多家知名企业的境内外资本运作。

Ms. Xu Liu, Vice President of Kingsoft Office, is in charge of the company's capital market activities and international business development. Prior to joining Kingsoft Office, Ms. Xu served as Managing Director in the Investment Banking Department of China International Capital Corporation (CICC), where she led numerous domestic and overseas capital market transactions for well-known companies in the TMT and consumer sectors.



张海龙 ZHANG Hailong

三六零首席财务官、董秘、董事
Director, Chief Financial Officer, and Board Secretary,
360 Security Technology Inc

张海龙先生，中国&美国注册会计师，现任三六零安全科技股份有限公司董事、CFO、董事会秘书，同时担任中央财经大学研究生客座导师、财政部第一届企业财务咨询专家、中国上市公司协会第三届财专委委员。

Mr. Hailong Zhang, a Certified Public Accountant in both China and the United States, currently serves as Director, Chief Financial Officer, and Board Secretary of 360 Security Technology Inc. He is also a Guest Supervisor for postgraduate students at the Central University of Finance and Economics, a Member of the First Corporate Finance Advisory Expert Committee of the Ministry of Finance, and a Member of the Third Financial Professional Committee of the China Association for Public Companies.



陆涛 Lucy LU

长电科技高级副总裁
Senior Vice President, JCET Group

陆涛女士于2024年3月出任长电科技高级副总裁。陆涛女士先后在日月光上海以及日月新集团服务二十余年，在客户及技术服务、销售市场、运营管理以及供应链管理等领域历任高级管理职务，拥有深厚的半导体封测行业的技术和客户服务管理经验。

Ms. Lucy Lu was appointed as Senior Vice President of JCET Group on March, 2024. Ms. Lu has over 20 years of experience at ASE Shanghai and ATX Group, where she held senior management positions in customer and technical services, sales and marketing, operations management, and supply chain management. She possesses extensive experience in the OSAT industry, with in-depth expertise in technology and customer service management.

主持人 / Moderator



徐宾 Robin XU

瑞银证券有限责任公司中国研究部总监
Head of China Research, UBS Securities Co. Ltd.

现任瑞银证券中国研究部总监。他获得伦敦政治经济学院经济学专业理学硕士和研究硕士学位以及牛津大学计算机专业硕士学位。2006年在瑞银开启职业生涯，深耕中国基础设施领域 19 年，所带领的中国工业团队长期居于行业领先地位。

Robin is Head of China Research of UBS. He holds MRes/MSc in Economics from the London School of Economics and Political Science, and an MSc in Computer Science from the University of Oxford. He joined UBS in 2006, covering China infrastructure sector for 19 years. Robin led the top ranked China Industrials team.

中国能否诞生世界级的医药企业？ Can China Cultivate World-Class Pharmaceutical Companies?

讨论嘉宾 / Panelists



高飞 GAO Fei

杭州奥泰生物技术股份有限公司董事长、总经理
Chairman and General Manager, Hangzhou Alltest Biotech Co., Ltd.

高飞先生，教授级高级工程师，现任杭州奥泰生物技术股份有限公司董事长、总经理。他曾任艾康生物、艾博生物等外资企业高管，并被选举为浙江省及钱塘区人大代表，担任钱塘区工商联副主席等职。他深耕生物医药领域近30年，荣获公安部、浙江省科技进步奖等多项荣誉，拥有30余项国内外发明专利，并主持了12项国家级、省市级重大科技项目。2021年，他成功带领奥泰生物在上海证券交易所上市。

Mr. Gao Fei is a Professor-level Senior Engineer and serves as the Chairman and General Manager of Hangzhou Allyest Biotech Co., Ltd. He previously held senior management positions at companies including Acon Biotech and Abon Biopharm. He has also been elected as a delegate to the Zhejiang Provincial People's Congress and the Qiantang District People's Congress, and serves as Vice Chairman of the Qiantang District Federation of Industry and Commerce. Mr. Gao has been deeply engaged in the biomedical field. He has won numerous awards, including the Science and Technology Progress Awards from the Ministry of Public Security and Zhejiang Province. He holds over 30 international and domestic invention patents and has led 12 major national and provincial-level science and technology projects. In 2021, he successfully led Atlas Biotechnology to its listing on the Shanghai Stock Exchange.



肖志华 XIAO Zhihua

上海奥浦迈生物科技股份有限公司董事长
Chairman and Managing Director, Shanghai OPM Biosciences Co., Ltd.

肖志华，上海奥浦迈生物科技股份有限公司董事长总经理，2007获美国纽约州立布法罗大学化学与生物工程博士学位，有超25年的细胞培养和生物制药开发经验，成功开发多种蛋白单抗表达细胞系、培养基和细胞培养工艺。2013年回国创立奥浦迈，专注细胞培养技术创新研发，以“培养基+CDMO”的商业模式，在浦东新区和临港建成超18000平米的培养基和CDMO研发生产基地。公司秉持“至臻工艺至善品质”的质量方针，细胞培养产品性能超过国际一流品牌，解决了生物制药核心原料培养基进口垄断“卡脖子”工程，确保了培养基的国产化和供应链稳定。

Dr. Zhihua Xiao is the founder and CEO of Shanghai OPM Biosciences Co., Ltd, a leading biotech company specializing in cell culture media and biologics CDMO services. With a Ph.D. obtained in 2007 from the University at Buffalo, the State University of New York, Dr. Xiao brings over 25 years of expertise in mammalian cell culture and therapeutic drug development to his leadership role. Prior to founding OPM, he held positions at Life Technologies Corporation, where he advanced from scientist to Senior R&D Manager during the period from 2007 to 2013. Following this, in 2013, Dr. Xiao assumed the role of Senior Director of Biologics CMC at Chempartner. Dr. Xiao's vision led to the establishment of OPM in 2014, driven by a mission to enhance biologics development efficiency and reduce manufacturing costs through the provision of high-quality cell culture media and CDMO services.



张连山 ZHANG Lianshan

江苏恒瑞医药股份有限公司全球研发总裁
Board Director and Executive Vice President, Jiangsu Hengrui Pharmaceuticals Co., Ltd.

张连山博士在德国Tubingen大学获有机化学博士，后赴美国Vanderbilt大学从事博士后研究。在加入恒瑞医药前，张连山博士先后在美国礼来和Marcadia Biotech就职，其中在礼来先后任高级化学家、研究顾问及首席研究科学家，在Marcadia Biotech担任资深研发总监等。自1988年至今，张连山博士从事多肽方法学和新药研发工作三十余年，在糖尿病等代谢性疾病治疗药物研发方面极有造诣。加入恒瑞医药后，张连山博士带领全球研发团队致力于高品质创新药研发，攻坚克难屡屡取得突破。目前，恒瑞医药已实现24款1类创新药和5款2类新药在中国获批上市，另有100多个自主创新产品正在进行临床开发，400多项临床研究在国内外开展，正为民族原研成果造福全球患者不懈努力。

Dr. Lianshan Zhang holds the position of Board Director and Executive Vice President of Jiangsu Hengrui Pharmaceuticals. Hengrui is widely recognized as the domestic leader in pharmaceutical R&D innovation in China. In 2010, Dr. Zhang joined Hengrui and takes the responsibility for R&D strategy and management of dozens of NMEs across the globe. Prior to Hengrui, he was engaged in the discovery and development of peptide/protein therapeutics for the treatment of metabolic diseases in Eli Lilly and Marcadia Biotech. Dr. Zhang obtained his Ph.D. in Organic Chemistry at University of Tubingen, and conducted his post-doctoral research at Vanderbilt University.

主持人 / Moderator



余文心 YU Wenxin

国泰海通证券研究所副所长
Deputy Head of Research Institute, Guotai Haitong Securities Co., Ltd.

余文心，国泰海通证券研究所副所长，生物医药行业首席分析师。她所带领的国泰海通生物医药研究团队2010-2023连续14年获得新财富、水晶球、金牛奖、福布斯、汤森路透等最佳卖方分析师，多次获得第一名。她拥有北京大学硕士及本科学位。团队分布在北京、上海、深圳、香港，立足中国，做全球视野的有历史观的研究。尤其擅长分析全球医药行业40年、中国医药行业20年、以及研究标的10年维度的深度研究，并以产业发展的全景图为基石挖掘个股。

Ms. Yu Wenxin serves as Deputy Director of the Guotai Haitong Securities Research Institute and Chief Analyst for the Biopharmaceutical Industry. The biopharmaceutical research team she leads has been recognized as the Best Sell-Side Analyst by New Fortune, Crystal Ball, Golden Bull Awards, Forbes, and Thomson Reuters for 14 consecutive years from 2010 to 2023, securing first place multiple times. With offices in Beijing, Shanghai, Shenzhen, and Hong Kong, the team conducts research grounded in China yet informed by a global perspective and historical insight. She specializes in in-depth analysis across three time horizons: 40 years for the global pharmaceutical industry, 20 years for China's pharmaceutical sector, and 10 years for specific research targets. The team identifies individual stocks by analyzing the comprehensive landscape of industrial development. Ms. Yu Wenxin holds both a master's and bachelor's degree from Peking University.

圆桌讨论 / Panel

高端制造新机遇：AI与能源高质量发展 High-End Equipment Manufacturing Topic

讨论嘉宾 / Panelists



张雨文 ZHANG Yuwen

绿的谐波传动科技股份有限公司总经理
General Manager, Leader Harmonious Drive System

张雨文现任苏州绿的谐波传动科技股份有限公司总经理、董事。在2021年被任命为总经理和2022年被任命为董事之前，张先生在公司担任董事会秘书和副总经理等职务。2013-2017 年间，他曾担任苏州国发创业投资控股有限公司投资经理、投资总监。张先生拥有伦敦帝国理工学院的应用数学硕士学位，以及伦敦政治经济学院的数学学士学位。

Mr. Zhang is the General Manager and Director of LeaderDrive. Before he was named General Manager in 2021 and Director in 2022, Mr. Zhang held leadership roles such as Board Secretary and Vice General Manager in the company. During 2013-2017, he served as an Investment Manager and Investment Director at Suzhou International Development Venture Capital. Mr. Zhang holds a Master's degree in Applied Mathematics from Imperial College London and a Bachelor's degree in Mathematics from the London School of Economics and Political Science.



胡顺靖 HU Shunqing

国电南瑞科技股份有限公司董事会秘书
Board Secretary, NARI Tech

华中科技大学电子材料与元器件和财务管理专业双学士、南京大学工商管理硕士，正高级会计师，注册会计师，南京大学专业学位硕士研究生行业导师。

历任南瑞集团有限公司监察审计部副主任、会计核算中心主任、财务资产部主任等职务，现任国电南瑞董事会秘书、投资者关系管理中心主任。

在企业管理、资本运营、财务数智化转型、会计核算、财务管理、内部审计等方面拥有丰富的理论和实践经验。

Hu holds double Bachelor's degrees in Electronic Components and Financial Management from Huazhong University of Science and Technology, and a Master of Business Administration (MBA) from Nanjing University. He is a Senior Accountant (professorial level) and Certified Public Accountant (CPA), and also serves as an Industry Mentor for Professional Master's Degree Candidates at Nanjing University.

Previously, he held the positions of Deputy Director of the Supervision and Audit Department, Director of the Accounting Center, and Director of the Finance and Assets Department at NARI Group Corporation. Currently, he serves as Secretary of the Board of Directors and Director of the Investor Relations Management Center at NARI Technology Co., Ltd.

He has extensive theoretical and practical experience in corporate management, capital operation, digital and intelligent transformation of finance, accounting, financial management, and internal audit.



许学亮 XU Xueliang

广东奥普特科技股份有限公司董事、副总经理、董事会秘书
Position of Director, Deputy General Manager, and Board Secretary,
OPT Machine Vision Tech

许学亮，男，1976年4月出生，中国国籍，大专学历。1997年7月至2003年11月，历任艾一资讯有限公司程序员、业务员、顾问、经理；2003年12月至2009年10月，历任用友软件股份有限公司业务经理、售前总监、渠道总监；2009年11月加入广东奥普特科技股份有限公司，现任公司董事、副总经理、董事会秘书。

Xu Xueliang, male, born in April 1976, Chinese nationality, holds a college diploma. From July 1997 to November 2003, he served successively as programmer, salesman, consultant, and manager at A-Yi Information Co., Ltd. From December 2003 to October 2009, he served as business manager, pre-sales director, and channel director at UFIDA Software Co., Ltd. He joined OPT Machine Vision Tech Co., Ltd. in November 2009 and currently holds the position of director, deputy general manager, and board secretary.

主持人 / Moderator



杜茜 Jacqueline DU

高盛（亚洲）证券董事总经理、
中国工业科技行业研究团队负责人
Managing Director, Head of China Industrial Technology Research,
Goldman Sachs Asia Securities Company

杜茜是中国工业科技行业研究团队负责人，也是2022-2025期间全球投资研究部亚太女性事务委员会Women's Network的联席主管。她于2008年加入高盛担任分析师，2023年升任董事总经理。杜茜2008年毕业于北京外国语大学，获得工商管理 and 英语文学双学士学位。

Jacqueline is head of China Industrial Technology research. She joined Goldman Sachs as an analyst in 2008 and was named managing director in 2023. She also co-led the Global Investment Research Asia Pacific Women's Network during 2022-2025. Jacqueline graduated from Beijing Foreign Studies University in 2008 with a double bachelor's degree in Business Management and English Literature.